Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety,
Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in
Combination with Toripalimab in Patients with Advanced Solid Tumors